Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

June 9, 2017

Primary Completion Date

July 5, 2022

Study Completion Date

August 24, 2022

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

NKTR-214

NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.

DRUG

Pembrolizumab

Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

DRUG

NKTR-214

NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.

DRUG

NKTR-214

NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.

DRUG

Cisplatin

Cisplatin will be dosed per the pharmacy manual

DRUG

Carboplatin

Carboplatin will be dosed per the pharmacy manual

DRUG

Nab paclitaxel

Nab-paclitaxel will be dosed per local practice and label

DRUG

Paclitaxel

Paclitaxel will be dosed per local practice and label

DRUG

Pemetrexed

Pemetrexed will be dosed per the pharmacy manual

DRUG

Atezolizumab

Atezolizumab will be dosed per current label indication

Trial Locations (38)

2100

Centre Hospitalier de Saint-Quentin, Saint-Quentin

3121

Epworth HealthCare, Richmond

10016

New York University Langone Medical Center, New York

10032

Columbia University Medical Center, New York

13585

Vivantes Klinikum Spandau, Berlin

19111

Fox Chase Cancer Center, Philadelphia

22031

Inova Melanoma and Skin Cancer Center, Fairfax

22927

LungenClinic Grosshansdorf, Großhansdorf

23538

Universitätsklinikum Schleswig-Holstein, Lübeck

24153

Blue Ridge Cancer Care, Roanoke

27705

Duke Clinical Research Institute, Durham

28040

Hospital Clínico San Carlos, Madrid

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28050

HM Universitario Sanchinarro, Madrid

30912

Augusta University - Augusta University Medical Center, Augusta

35016

Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria

37203

Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville

38138

West Cancer Center, Germantown

46026

Hospital Universitari i Politècnic La Fe, Valencia

48202

Henry Ford Hospital, Detroit

53226

Froedtert & the Medical College of Wisconsin Froedtert Hospital, Milwaukee

55426

Park Nicollet - Frauenshuh Cancer Center, Saint Louis Park

58675

Lungenklinik Hemer, Hemer

59101

St. Vincent Frontier Cancer Center, Billings

63156

Washington University School of Medicine in St. Louis, St Louis

68198

University of Nebraska Medical Center, Omaha

70376

Robert-Bosch-Krankenhaus, Stuttgart

70816

Ochsner Medical Center, New Orleans

72703

Highlands Oncology Group, PA - North Hills, Fayetteville

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

82131

Asklepios Fachkliniken München-Gauting, Gauting

89169

Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas

94115

California Pacific Medical Center, San Francisco

98405

Northwest Medical Specialties, Tacoma

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08035

Hospital Universitario Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Nektar Therapeutics

INDUSTRY

NCT03138889 - Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter